Sonata Therapeutics
Wenlong Xu is an accomplished professional in the field of molecular and synthetic biology, currently serving as the Director of Molecular & Synthetic Biology at Sonata Therapeutics since November 2022, after previously holding the position of Associate Director. Prior to this role, Wenlong Xu worked as a Scientist at Biogen from August 2020 to November 2022 and was a Postdoctoral Associate at the Massachusetts Institute of Technology from December 2018 to August 2020. Wenlong Xu's earlier experience includes serving as a Program Aide at Colorado State University and as a Graduate Research Assistant, where responsibilities included research and development as well as teaching assistance for undergraduate courses. Wenlong Xu holds a Doctor of Chemical Engineering with a focus on Bioengineering from Colorado State University and obtained a Bachelor of Bioengineering from Northwest A&F University.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.